ABBV vs REGN
By Alex · Tickerpine
AbbVie Inc. vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | REGN |
|---|---|---|
| Price | $248.76 | $797.99 |
| Market cap | $439.59B | $82.16B |
| P/E ratio | 70.5 | 19.7 |
| ROE | — | 14.04% |
| Profit margin | 9.80% | 27.87% |
| Revenue growth | 10.20% | 16.70% |
| Dividend yield | 2.77% | 0.47% |
| Beta | 0.28 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs REGN in plain English
- ABBV is the bigger company — about 5.4× the market cap of REGN.
- REGN is cheaper on earnings (P/E 19.7 vs 70.5).
- REGN is growing revenue faster (17% vs 10%).
- ABBV has the higher dividend yield (2.77% vs 0.47%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.